Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson’s disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER

Open-label extensions [studies SP516 (NCT00501969) and SP715 (NCT00594386)] of the CLEOPATRA-PD and PREFER studies were conducted to evaluate the safety, tolerability and efficacy of the dopaminergic agonist, rotigotine, over several years of follow-up in patients with advanced Parkinson’s disease (...

Fuld beskrivelse

Na minha lista:

Bibliografiske detaljer
Main Authors:	LeWitt, Peter A., Boroojerdi, Babak, Surmann, Erwin, Poewe, Werner
Format:	Artigo
Sprog:	Inglês
Udgivet:	Springer Vienna 2012
Fag:	Neurology and Preclinical Neurological Studies - Original Article
Online adgang:	https://ncbi.nlm.nih.gov/pmc/articles/PMC3687107/ https://ncbi.nlm.nih.gov/pubmed/23208198 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00702-012-0925-5
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!

Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson’s disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER

Lignende værker